BDR Blonder Tongue Laboratories Inc

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of TG Therapeutics, Inc. (NASDAQ:TGTX), IRHYTHM TECH (NASDAQ:IRTC), Sierra Metals Inc. (NYSE:SMTS), Zomedica Pharmaceuticals Corp. (NYSE:ZOM), Blonder Tongue Laboratories, Inc. (NYSE:BDR), and Newtek Business Services Corp. (NASDAQ:NEWT), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

TGTX DOWNLOAD: http://Capital-Review.com/register/?so=TGTX IRTC DOWNLOAD: http://Capital-Review.com/register/?so=IRTC SMTS DOWNLOAD: http://Capital-Review.com/register/?so=SMTS ZOM DOWNLOAD: http://Capital-Review.com/register/?so=ZOM BDR DOWNLOAD: http://Capital-Review.com/register/?so=BDR NEWT DOWNLOAD: http://Capital-Review.com/register/?so=NEWT

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Capital Review, available for free download at the links above, examine TG Therapeutics, Inc. (NASDAQ:TGTX), IRHYTHM TECH (NASDAQ:IRTC), Sierra Metals Inc. (NYSE:SMTS), Zomedica Pharmaceuticals Corp. (NYSE:ZOM), Blonder Tongue Laboratories, Inc. (NYSE:BDR), and Newtek Business Services Corp. (NASDAQ:NEWT) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

TG THERAPEUTICS, INC. (TGTX) REPORT OVERVIEW

TG Therapeutics' Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, TG Therapeutics reported revenue of $0.04MM vs $0.04MM (unchanged) and analysts estimated basic earnings per share -$0.69 vs -$0.46. For the twelve months ended December 31st, 2018 vs December 31st, 2017, TG Therapeutics reported revenue of $0.15MM vs $0.15MM (unchanged) and analysts estimated basic earnings per share -$2.30 vs -$1.91. Analysts expect earnings to be released on May 14th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.59. The estimated EPS forecast for the next fiscal year is -$1.63 and is expected to report on April 4th, 2019.

To read the full TG Therapeutics, Inc. (TGTX) report, download it here: http://Capital-Review.com/register/?so=TGTX

-----------------------------------------

IRHYTHM TECH (IRTC) REPORT OVERVIEW

IRHYTHM TECH's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, IRHYTHM TECH reported revenue of $43.16MM vs $28.18MM (up 53.12%) and analysts estimated basic earnings per share -$0.61 vs -$0.48. For the twelve months ended December 31st, 2018 vs December 31st, 2017, IRHYTHM TECH reported revenue of $147.29MM vs $98.51MM (up 49.52%) and analysts estimated basic earnings per share -$2.02 vs -$1.30. Analysts expect earnings to be released on May 1st, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was -$0.47. The estimated EPS forecast for the next fiscal year is -$0.91 and is expected to report on February 11th, 2020.

To read the full IRHYTHM TECH (IRTC) report, download it here: http://Capital-Review.com/register/?so=IRTC

-----------------------------------------

SIERRA METALS INC. (SMTS) REPORT OVERVIEW

Sierra Metals' Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Sierra Metals reported revenue of $55.02MM vs $51.17MM (up 7.52%) and analysts estimated basic earnings per share -$0.01 vs $0.01. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Sierra Metals reported revenue of $232.37MM vs $205.12MM (up 13.29%) and analysts estimated basic earnings per share $0.12 vs -$0.03. Analysts expect earnings to be released on May 8th, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was $0.07. The estimated EPS forecast for the next fiscal year is $0.31 and is expected to report on March 26th, 2020.

To read the full Sierra Metals Inc. (SMTS) report, download it here: http://Capital-Review.com/register/?so=SMTS

-----------------------------------------

ZOMEDICA PHARMACEUTICALS CORP. (ZOM) REPORT OVERVIEW

Zomedica Pharmaceuticals' Recent Financial Performance

Analysts expect earnings to be released on May 21st, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.02.

To read the full Zomedica Pharmaceuticals Corp. (ZOM) report, download it here: http://Capital-Review.com/register/?so=ZOM

-----------------------------------------

BLONDER TONGUE LABORATORIES, INC. (BDR) REPORT OVERVIEW

Blonder Tongue Laboratories' Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Blonder Tongue Laboratories reported revenue of $5.44MM vs $5.57MM (down 2.32%) and analysts estimated basic earnings per share -$0.08 vs $0.03. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Blonder Tongue Laboratories reported revenue of $21.71MM vs $23.28MM (down 6.77%) and analysts estimated basic earnings per share -$0.15 vs -$0.05. Analysts expect earnings to be released on May 10th, 2019. The report will be for the fiscal period ending March 31st, 2019.

To read the full Blonder Tongue Laboratories, Inc. (BDR) report, download it here: http://Capital-Review.com/register/?so=BDR

-----------------------------------------

NEWTEK BUSINESS SERVICES CORP. (NEWT) REPORT OVERVIEW

Newtek Business Services' Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Newtek Business Services reported revenue of $14.66MM vs $10.42MM (up 40.73%) and analysts estimated basic earnings per share $0.40 vs $1.03 (down 61.17%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, Newtek Business Services reported revenue of $49.52MM vs $38.91MM (up 27.24%) and analysts estimated basic earnings per share $1.91 vs $2.25 (down 15.11%). Analysts expect earnings to be released on May 1st, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.44. The estimated EPS forecast for the next fiscal year is $2.23 and is expected to report on March 4th, 2020.

To read the full Newtek Business Services Corp. (NEWT) report, download it here: http://Capital-Review.com/register/?so=NEWT

-----------------------------------------

ABOUT CAPITAL REVIEW

Capital Review is a nationally recognized publisher of financial analysis, research reports, and exclusive market reporting. Institutional investors, registered brokers, professional traders, and personal investment advisers rely on Capital Review to quantify public company valuations, discover opportunity across asset classes, stay informed about market-moving events, and read exclusive analysis of important material developments. With 14 offices worldwide, Capital Review staffs and manages certified and registered financial professionals, including Chartered Financial Analyst® (CFA®) designation holders and FINRA® BrokerCheck® certified individuals with current and valid CRD® number designations, to enable continuous coverage of topics relevant to its regular active reader base.

REGISTERED MEMBER STATUS

Capital Review's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Capital Review's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Capital Review have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Capital Review's Compliance department by Phone, at +1 (410) 280-7496, or by E-mail at compliance@Capital-Review.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Capital Review, Capital Review members, and/or Capital Review affiliates are not responsible for any gains or losses that result from the opinions expressed. Capital Review makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Capital Review has not been compensated for the publication of this press release by any of the above mentioned companies. Capital Review is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact: Morena Zambada, Media Department Office: +1 (410) 280-7496 E-mail: media@Capital-Review.com

© 2019 Capital Review. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Capital-Review.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.